Our partnership with Daiichi Sankyo Company, Limited (Daiichi Sankyo) is enduring and aligns with our science-led strategy in oncology, which is based on four key scientific platforms: Immuno-Oncology, Antibody-Drug Conjugates, DNA Damage Response, and Tumor Drivers and Resistance. In March 2019, we entered into a global development and commercialisation agreement with Daiichi Sankyo for trastuzumab deruxtecan (ENHERTU), a proprietary antibody-drug conjugate (ADC) and targeted medicine for cancer treatment in HER2+ tumors. As of July 2020, the collaboration with Daiichi Sankyo has been extended to include a new global development and commercialisation agreement for DS-1062, Daiichi Sankyo’s proprietary TROP2 (trophoblast cell-surface antigen 2) directed ADC. DS-1062 is currently in development for the treatment of multiple tumors that commonly express the cell-surface glycoprotein TROP2, which is overexpressed in the majority of non-small cell lung cancers and breast cancers.